Literature DB >> 19302181

Effect of hyponatraemia on outcomes following orthotopic liver transplantation.

William A Hackworth1, Douglas M Heuman, Arun J Sanyal, Robert A Fisher, Richard K Sterling, Velimir A Luketic, Mitchell L Shiffman, Daniel G Maluf, Adrian H Cotterell, Marc P Posner, Richard T Stravitz.   

Abstract

BACKGROUND: Hyponatraemia increases risk of adverse outcomes following orthotopic liver transplantation (OLT), but it is unclear whether improvement of pretransplant hyponatraemia ameliorates post-transplant complications. AIMS: To assess impact of pretransplant hyponatraemia on post-transplant outcomes.
METHODS: We performed a retrospective analysis of 213 patients with cirrhosis who underwent liver transplantation. Patients with serum sodium <or=130 mEq/L immediately before transplantation ('hyponatraemia at OLT'; n=34) were compared with those who had experienced hyponatraemia but subsequently improved to a serum sodium >130 mEq/L at transplantation ('resolved hyponatraemia'; n=56) and to those without history of hyponatraemia before transplantation ('never hyponatraemic'; n=123). Primary endpoint was survival at 180 days post-OLT. Secondary outcomes included time until discharge alive, complications during hospitalization, length of time ventilated and length of post-transplant intensive care unit stay.
RESULTS: There was no survival difference at 180 days post-OLT between groups. After transplantation, patients with either hyponatraemia at OLT or resolved hyponatraemia had longer time until discharge alive and had higher rates of delirium, acute renal failure, acute cellular rejection and infection than those who were never hyponatraemic. As compared with patients with hyponatraemia at OLT, those with resolved hyponatraemia were more likely to be discharged alive within 3 weeks, but other outcomes, including survival, did not differ significantly.
CONCLUSIONS: We conclude that hyponatraemia at any time before liver transplantation is associated with adverse post-transplant outcome, even when hyponatraemia has resolved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302181     DOI: 10.1111/j.1478-3231.2009.01982.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  28 in total

Review 1.  Vasopressin receptor antagonists.

Authors:  Biff F Palmer
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

Review 2.  Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.

Authors:  José Víctor Jiménez; Diego Luis Carrillo-Pérez; Rodrigo Rosado-Canto; Ignacio García-Juárez; Aldo Torre; David Kershenobich; Eduardo Carrillo-Maravilla
Journal:  Dig Dis Sci       Date:  2017-05-13       Impact factor: 3.199

Review 3.  Perioperative monitoring in liver transplant patients.

Authors:  Shweta Singh; Vaibhav Nasa; Manish Tandon
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

4.  Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation.

Authors:  Michael D Leise; Byung Cheol Yun; Joseph J Larson; Joanne T Benson; Ju Dong Yang; Terry M Therneau; Charles B Rosen; Julie K Heimbach; Scott W Biggins; W Ray Kim
Journal:  Liver Transpl       Date:  2014-06       Impact factor: 5.799

5.  Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis.

Authors:  Vishwadeep Ahluwalia; Douglas M Heuman; George Feldman; James B Wade; Leroy R Thacker; Edith Gavis; HoChong Gilles; Ariel Unser; Melanie B White; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2014-08-08       Impact factor: 25.083

Review 6.  Hyponatraemia: more than just a marker of disease severity?

Authors:  Robert W Schrier; Shailendra Sharma; Dmitry Shchekochikhin
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

7.  Hyponatremia is associated with more severe biliary disease.

Authors:  Michael John Zobel; Lygia Stewart
Journal:  World J Gastrointest Surg       Date:  2020-02-27

8.  Hyponatremia and Hepatorenal Syndrome.

Authors:  Arpan Mohanty; Guadalupe Garcia-Tsao
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04

9.  Analysis of infections in the first 3-month after living donor liver transplantation.

Authors:  Chuan Li; Tian-Fu Wen; Kai Mi; Chuan Wang; Lu-Nan Yan; Bo Li
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

10.  Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

Authors:  Shahid Habib; Thomas D Boyer
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.